Allogeneic CAR T-cell therapy for relapsed or refractory multiple myeloma: Results from the UNIVERSAL trial

Therapy with B-cell maturation antigen (BCMA)-directed autologous chimeric antigen receptor...

ASH 2020 discussion: Looking for the best partner for lenalidomide maintenance after auto-SCT

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma...

Preliminary results of phase I trials on safety and tolerability of bispecific antibodies and BiTEs for RRMM

At the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, held in...

Fast track designation and phase II trial initiation with elranatamab, a BCMA/CD3 bispecific antibody

The first patient with relapsed/refractory multiple myeloma (MM) has been given a dose of...

Latest advances in AL amyloidosis treatment

During the 6th World Congress on Controversies in Multiple Myeloma (COMy) the Multiple Myeloma Hub spoke to Giampaolo Merlini, University of Pavia, Pavia,...

Is re-treatment possible with anti-CD38 therapies?

During the 6th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub spoke to Saad Usmani, Levine Cancer Institute,...

TOURMALINE-MM2 trial: Ixazomib with Rd versus Rd in newly diagnosed patients with MM

Transplant ineligible patients who are diagnosed with multiple myeloma (MM) are a diverse group; some are fit while...

Why do we need to harmonize the use of MRD in MM?

During the 6th World Congress on Controversies in Multiple Myeloma (COMy) the Multiple Myeloma Hub spoke to Bruno Paiva, University of Navarra,...

What are the unmet needs in AL amyloidosis in Europe?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Efstathios Kastritis,...

Accelerated approval granted by FDA for daratumumab sc + VCd for AL amyloidosis in light of the phase III ANDROMEDA trial updated results

The subcutaneous formulation of daratumumab + hyaluronidase...

Prognostic biomarkers and staging in AL amyloidosis

In this second article of the ‘Amyloidosis Series’, we will discuss the prognosis and risk stratification models for AL amyloidosis and summarize...

Editorial theme | Incidence and diagnosis of AL amyloidosis

Amyloidosis refers to a rare and heterogeneous group of hematological disorders characterized by extracellular proliferation of proteins in...